Roth MKM analyst Jason Wittes resumed coverage of Beyond Air with a Buy rating and $2 price target. The analyst believes the company’s LungFit PH has significant advantages over current canister or cartridge-based nitrous oxide systems, positioning it to be “best in class.” Execution risks including the need for additional financing are already priced into the shares, creating upside from current levels, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XAIR:
- Beyond Air Faces Nasdaq Delisting Risk and Executive Resignation
- Beyond Air price target lowered to $1 from $3.50 at Piper Sandler
- Beyond Air sees FY25 revenue greater than $10M, consensus $9.42M
- Beyond Air reports Q1 EPS (27c), consensus (32c)
- Beyond Air publishes inhaled nitric oxide safety data in Scientific Reports